BioCentury | Apr 4, 2020
Product Development

Dealmaking in a pandemic: partnerships speeding COVID-19 countermeasures

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | May 25, 2015
Finance

Innovation underfed

Stephen Hansen, Associate Editor Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone with...
BioCentury | Jul 24, 2014
Strategy

AD mission in the U.K.

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly £120 million ($205 million) from U.K.-based organizations for a series of research initiatives that span R&D from discovery to...
BioCentury | Mar 12, 2014
Politics & Policy

IMI launches GETREAL project

Europe's Innovative Medicines Initiative launched the GETREAL (see BioCentury, Dec. 23, 2013) . BC Staff...
BioCentury | Feb 13, 2014
Politics & Policy

IMI launches antibiotic discovery project

Europe's Innovative Medicines Initiative launched the European Gram-Negative Antibacterial Engine (ENABLE) project to progress antibacterial research programs through discovery and Phase I testing. The goal is to move at least one novel antibacterial for Gram-negative...
BioCentury | May 25, 2013
Politics & Policy

C-Path, IMI consortia in biomarkers deal

Consortia led by the Critical Path Institute and Europe's Innovative Medicines Initiative (IMI) partnered to develop new biomarkers to predict, diagnose and monitor drug-induced injury to the liver, kidney and vascular system. The Predictive Safety...
BioCentury | Feb 7, 2013
Cover Story

2012 gets a new deal

SciBX 's second annual comprehensive analysis of public-private partnerships and early stage venture financing activity reveals that government institutions and organizations are taking a significant role in forming and funding partnerships, and California-based companies are...
BioCentury | Jan 24, 2013
Strategy

IMI's collaborative chemistry

Europe's Innovative Medicines Initiative has launched seven new public-private partnerships with a total budget of €237 million ($313 million). In contrast to many of the organization's disease-focused projects, three of the new consortia are taking...
BioCentury | Dec 19, 2012
Politics & Policy

IMI expanding ND4BB

Europe's Innovative Medicines Initiative is expanding its NewDrugs4BadBugs (ND4BB) initiative, which was launched in May to support the development of new antibiotics. The details came in IMI's eighth call for proposals to fund public-private partnerships...
Items per page:
1 - 10 of 29
BioCentury | Apr 4, 2020
Product Development

Dealmaking in a pandemic: partnerships speeding COVID-19 countermeasures

COVID-19 may be putting the brakes on a broad swath of biopharma deals, but it has also triggered a host of partnerships for coronavirus countermeasures, pushing vaccine deals to their highest numbers in years. Many...
BioCentury | Sep 5, 2016
Strategy

Back to School 2016: Haste, not waste

As researchers in industry and academia rapidly unravel molecular disease mechanisms and drug developers become more adept at intervening in disease pathways with drugs targeted to specific populations, the current clinical development paradigm cannot keep...
BioCentury | May 25, 2015
Finance

Innovation underfed

Stephen Hansen, Associate Editor Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone with...
BioCentury | Jul 24, 2014
Strategy

AD mission in the U.K.

The U.K. government is responding to calls for a dementia therapy by 2025 by securing nearly £120 million ($205 million) from U.K.-based organizations for a series of research initiatives that span R&D from discovery to...
BioCentury | Mar 12, 2014
Politics & Policy

IMI launches GETREAL project

Europe's Innovative Medicines Initiative launched the GETREAL (see BioCentury, Dec. 23, 2013) . BC Staff...
BioCentury | Feb 13, 2014
Politics & Policy

IMI launches antibiotic discovery project

Europe's Innovative Medicines Initiative launched the European Gram-Negative Antibacterial Engine (ENABLE) project to progress antibacterial research programs through discovery and Phase I testing. The goal is to move at least one novel antibacterial for Gram-negative...
BioCentury | May 25, 2013
Politics & Policy

C-Path, IMI consortia in biomarkers deal

Consortia led by the Critical Path Institute and Europe's Innovative Medicines Initiative (IMI) partnered to develop new biomarkers to predict, diagnose and monitor drug-induced injury to the liver, kidney and vascular system. The Predictive Safety...
BioCentury | Feb 7, 2013
Cover Story

2012 gets a new deal

SciBX 's second annual comprehensive analysis of public-private partnerships and early stage venture financing activity reveals that government institutions and organizations are taking a significant role in forming and funding partnerships, and California-based companies are...
BioCentury | Jan 24, 2013
Strategy

IMI's collaborative chemistry

Europe's Innovative Medicines Initiative has launched seven new public-private partnerships with a total budget of €237 million ($313 million). In contrast to many of the organization's disease-focused projects, three of the new consortia are taking...
BioCentury | Dec 19, 2012
Politics & Policy

IMI expanding ND4BB

Europe's Innovative Medicines Initiative is expanding its NewDrugs4BadBugs (ND4BB) initiative, which was launched in May to support the development of new antibiotics. The details came in IMI's eighth call for proposals to fund public-private partnerships...
Items per page:
1 - 10 of 29